Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms
Abstract Background The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-a...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-024-03814-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544561754636288 |
|---|---|
| author | Mariah A. Manter Kirstin B. Birtwell James Bath Nora D. B. Friedman Christopher J. Keary Ann M. Neumeyer Michelle L. Palumbo Robyn P. Thom Emily Stonestreet Hannah Brooks Kelly Dakin Jacob M. Hooker Christopher J. McDougle |
| author_facet | Mariah A. Manter Kirstin B. Birtwell James Bath Nora D. B. Friedman Christopher J. Keary Ann M. Neumeyer Michelle L. Palumbo Robyn P. Thom Emily Stonestreet Hannah Brooks Kelly Dakin Jacob M. Hooker Christopher J. McDougle |
| author_sort | Mariah A. Manter |
| collection | DOAJ |
| description | Abstract Background The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings. This work aims to empower healthcare providers, especially primary care providers (PCPs), with guidelines for the recognition and safe pharmacologic management of common co-occurring psychiatric and behavioral conditions in ASD. Methods Lurie Center for Autism medical providers, who have extensive experience in ASD care, delineated approaches for recognition and pharmacological treatment of sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability tailored to ASD patients. Pharmacological guidelines were iteratively refined until consensus was reached. Treatment differences relative to standard of care (SOC) of non-autistic individuals are noted. Key literature and clinical trial results were reviewed to supplement clinical experience. Results The pharmacological treatment pathways reflect how appropriate medication options for ASD patients can depend on many factors unique to the patient and can differ from established non-autistic SOC. Key takeaways include: For sleep disturbances in ASD, initial strategies align with non-autistic SOC, emphasizing sleep hygiene and melatonin use. First-line recommendations for treating ADHD, anxiety, and depression in ASD differ from non-autistic SOC; α2-adrenergic agonists are more suitable than stimulants for some ASD-ADHD patients, buspirone and mirtazapine are preferred to selective serotonin reuptake inhibitors (SSRIs) for anxiety, and duloxetine, mirtazapine, bupropion, and vortioxetine are recommended ahead of SSRIs for depression. Addressing irritability in ASD requires interdisciplinary evaluation of contributing factors, and guanfacine, risperidone, or aripiprazole may be appropriate, depending on severity. Conclusions Recognition and treatment of co-occurring psychiatric and behavioral conditions in autistic patients must account for differences in clinical presentation and medication effectiveness and tolerability. Drawing on evidence-based clinical insights, these guidelines seek to support PCPs in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD. |
| format | Article |
| id | doaj-art-0cd81bf9b00e4f498276ca6d01576843 |
| institution | Kabale University |
| issn | 1741-7015 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj-art-0cd81bf9b00e4f498276ca6d015768432025-01-12T12:26:55ZengBMCBMC Medicine1741-70152025-01-0123113110.1186/s12916-024-03814-0Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptomsMariah A. Manter0Kirstin B. Birtwell1James Bath2Nora D. B. Friedman3Christopher J. Keary4Ann M. Neumeyer5Michelle L. Palumbo6Robyn P. Thom7Emily Stonestreet8Hannah Brooks9Kelly Dakin10Jacob M. Hooker11Christopher J. McDougle12Lurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalLurie Center for Autism, Massachusetts General HospitalAbstract Background The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings. This work aims to empower healthcare providers, especially primary care providers (PCPs), with guidelines for the recognition and safe pharmacologic management of common co-occurring psychiatric and behavioral conditions in ASD. Methods Lurie Center for Autism medical providers, who have extensive experience in ASD care, delineated approaches for recognition and pharmacological treatment of sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability tailored to ASD patients. Pharmacological guidelines were iteratively refined until consensus was reached. Treatment differences relative to standard of care (SOC) of non-autistic individuals are noted. Key literature and clinical trial results were reviewed to supplement clinical experience. Results The pharmacological treatment pathways reflect how appropriate medication options for ASD patients can depend on many factors unique to the patient and can differ from established non-autistic SOC. Key takeaways include: For sleep disturbances in ASD, initial strategies align with non-autistic SOC, emphasizing sleep hygiene and melatonin use. First-line recommendations for treating ADHD, anxiety, and depression in ASD differ from non-autistic SOC; α2-adrenergic agonists are more suitable than stimulants for some ASD-ADHD patients, buspirone and mirtazapine are preferred to selective serotonin reuptake inhibitors (SSRIs) for anxiety, and duloxetine, mirtazapine, bupropion, and vortioxetine are recommended ahead of SSRIs for depression. Addressing irritability in ASD requires interdisciplinary evaluation of contributing factors, and guanfacine, risperidone, or aripiprazole may be appropriate, depending on severity. Conclusions Recognition and treatment of co-occurring psychiatric and behavioral conditions in autistic patients must account for differences in clinical presentation and medication effectiveness and tolerability. Drawing on evidence-based clinical insights, these guidelines seek to support PCPs in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD.https://doi.org/10.1186/s12916-024-03814-0AutismPsychopharmacologyAutism-competent careGuidelinesPrimary careSleep |
| spellingShingle | Mariah A. Manter Kirstin B. Birtwell James Bath Nora D. B. Friedman Christopher J. Keary Ann M. Neumeyer Michelle L. Palumbo Robyn P. Thom Emily Stonestreet Hannah Brooks Kelly Dakin Jacob M. Hooker Christopher J. McDougle Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms BMC Medicine Autism Psychopharmacology Autism-competent care Guidelines Primary care Sleep |
| title | Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms |
| title_full | Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms |
| title_fullStr | Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms |
| title_full_unstemmed | Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms |
| title_short | Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms |
| title_sort | pharmacological treatment in autism a proposal for guidelines on common co occurring psychiatric symptoms |
| topic | Autism Psychopharmacology Autism-competent care Guidelines Primary care Sleep |
| url | https://doi.org/10.1186/s12916-024-03814-0 |
| work_keys_str_mv | AT mariahamanter pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT kirstinbbirtwell pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT jamesbath pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT noradbfriedman pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT christopherjkeary pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT annmneumeyer pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT michellelpalumbo pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT robynpthom pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT emilystonestreet pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT hannahbrooks pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT kellydakin pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT jacobmhooker pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms AT christopherjmcdougle pharmacologicaltreatmentinautismaproposalforguidelinesoncommoncooccurringpsychiatricsymptoms |